Ambitious new efforts to expand healthcare coverage may be ruled out in the near future.
WASHINGTON, D.C. - Policy makers on Capitol Hill are staking out positions for the anticipated debate on overhauling the nation's healthcare system.
A number of powerful legislators involved in steering reform legislation through Congress are crafting strategies for gaining consensus-and also filling the void while the new administration lines up its healthy policy and administrative staff. The economic crisis and soaring budget deficits, however, may rule out ambitious new initiatives to expand coverage for the near future.
A more practical strategy, as suggested by leaders of the House, is a piecemeal approach to health reform. House Ways & Means Health Subcommittee Chairman Pete Stark (D-Calif.) is urging quick action on legislation to reauthorize or expand the State Children's Health Insurance Program (SCHIP) and to bolster state Medicaid programs.
SENATE MANEUVERS
Senate leaders appear more open to broader reform initiatives, as seen in the comprehensive "Health Reform 2009" proposal unveiled by Senate Finance Committee chairman Max Baucus (D-Mont.) in November. Sen. Ted Kennedy (D-Mass.), head of the Senate Health, Education, Labor & Pensions (HELP) Committee, has been meeting with key stakeholders electronically with an eye on proposing a "one bill" legislative strategy.
"We want 80 votes for healthcare reform in the Senate," says a Baucus aide, emphasizing the importance of crafting bipartisan legislation based on a consensus approach. That will require support for any Democratic reform initiative from Republican leaders on health policy: Senators Mike Enzi of the HELP Committee, and Charles Grassley and Orrin Hatch on Finance.
Baucus's proposal aims to achieve universal coverage by mandating that all Americans have health insurance, a marked difference from reform proposals articulated by President-elect Barack Obama. Otherwise, the Baucus plan echoes many Obama concepts, such as expanding public safety-net programs and reforming the insurance market to improve coverage options for those without employer-based benefits.
Companies that want to sell through a Health Insurance Exchange to individuals and small businesses would have to meet minimum benefit standards, compete with a new public plan option and comply with guaranteed issue and community rating policies.
While Baucus retains the employer-based healthcare system, his plan acknowledges the need to revise existing tax incentives related to health benefits. Instead of eliminating the tax exclusion for employer-based health insurance premiums, as proposed by Sen. John McCain, the plan proposes more targeted reforms of the system, such as capping the amount of premiums that can be excluded from wages, based on the value of the benefits or individual income.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More